GS-4182
Sponsors
Gilead Sciences Inc., Gilead Sciences
Conditions
HIV-1 InfectionHIV-1-InfectionHIV-1-infection
Phase 2
Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
Active, not recruitingNCT06544733
Start: 2024-08-20End: 2029-06-30Target: 675Updated: 2026-01-05
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
TerminatedNCT06613685
Start: 2024-10-21End: 2026-03-16Updated: 2026-03-31
An Operationally Seamless Phase 2/3, Randomized, Active Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination with GS-4182 Versus Biktarvy in Treatment Naive People with HIV-1
SuspendedCTIS2024-512505-66-00
Start: 2025-03-03Target: 186Updated: 2025-10-29
An Operationally Seamless Phase 2/3, Randomized, Active -Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1
Not yet recruitingCTIS2024-511054-50-00
Target: 35Updated: 2025-04-02